Hudson Bay Capital Management
KRYS icon

Hudson Bay Capital Management’s Krystal Biotech KRYS Stock Holding History

Hudson Bay Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,300
Closed -$336K – 1532
2026
Q1 		$336K Buy
+1,300
New +$346K ﹤0.01% 1019
2020
Q4 		– Sell
-22,500
Closed -$969K – 647
2020
Q3 		$969K Sell
22,500
-12,500
-36% -$543K 0.01% 432
2020
Q2 		$1.45M Buy
+35,000
New +$1.68M 0.03% 344

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Hudson Bay Capital Management's KRYS Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 1,300 shares — an estimated $336K sold.

Hudson Bay Capital Management first reported a position in KRYS in Q2 2020 and held it in 3 quarters. The position peaked at $1.45M in Q2 2020. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,300 Krystal Biotech shares in Q2 2026, an estimated $336K.
  • Hudson Bay Capital Management first reported a position in Krystal Biotech in Q2 2020 and held it in 3 quarters.
  • Hudson Bay Capital Management's Krystal Biotech position peaked at $1.45M in Q2 2020.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.